Vantage Consulting Group Inc Organon & Co. Transaction History

Vantage Consulting Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$16.59 - $23.77 $6,453 - $9,246	389 Added 3.35%	12,005 $208,000
Q2 2023 Aug 11, 2023	BUY	$19.27 - $24.63 $20,291 - $25,935	1,053 Added 9.97%	11,616 $241,000
Q1 2023 May 10, 2023	BUY	$21.42 - $32.08 $34,421 - $51,552	1,607 Added 17.94%	10,563 $248,000
Q4 2022 Feb 13, 2023	BUY	$23.31 - $28.61 $7,948 - $9,756	341 Added 3.96%	8,956 $250,000
Q3 2022 Nov 14, 2022	BUY	$23.4 - $34.25 $42,822 - $62,677	1,830 Added 26.97%	8,615 $202,000
Q2 2022 Aug 09, 2022	BUY	$31.66 - $38.9 $11,935 - $14,665	377 Added 5.88%	6,785 $229,000
Q1 2022 May 16, 2022	SELL	$30.45 - $39.36 $80,814 - $104,461	-2,654 Reduced 29.29%	6,408 $224,000
Q4 2021 Feb 14, 2022	BUY	$28.67 - $37.13 $54,817 - $70,992	1,912 Added 26.74%	9,062 $276,000
Q3 2021 Nov 10, 2021	SELL	$28.63 - $35.64 $13,685 - $17,035	-478 Reduced 6.27%	7,150 $234,000
Q2 2021 Aug 11, 2021	BUY	$28.45 - $38.0 $217,016 - $289,864	7,628 New	7,628 $231,000

791

193M

1.71M

865K

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $3.75B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vantage Consulting Group Inc with notifications on news.